Busa Prabhakar, Kankala Ranjith Kumar, Deng Jin-Pei, Liu Chen-Lun, Lee Chia-Hung
Department of Life Science, National Dong Hwa University, Hualien 97401, Taiwan.
College of Chemical Engineering, Huaqiao University, Xiamen 361021, China.
Nanomaterials (Basel). 2022 Oct 21;12(20):3693. doi: 10.3390/nano12203693.
Recently, the development of anti-cancer approaches using different physical or chemical pathways has shifted from monotherapy to synergistic therapy, which can enhance therapeutic effects. As a result, enormous efforts have been devoted to developing various delivery systems encapsulated with dual agents for synergistic effects and to combat cancer cells acquired drug resistance. In this study, we show how to make Institute of Bioengineering and Nanotechnology (IBN)-1-based mesoporous silica nanoparticles (MSNs) for multifunctional drug delivery to overcome drug resistance cancer therapy. Initially, curcumin (Cur)-embedded IBN-1 nanocomposites (IBN-1-Cur) are synthesized in a simple one-pot co-condensation and then immobilized with the prodrug of Cisplatin (CP) on the carboxylate-modified surface (IBN-1-Cur-CP) to achieve photodynamic therapy (PDT) and chemotherapy in one platform, respectively, in the fight against multidrug resistance (MDR) of MES-SA/DX5 cancer cells. The Pluronic F127 triblock copolymer, as the structure-directing agent, in nanoparticles acts as a p-glycoprotein (p-gp) inhibitor. These designed hybrid nanocomposites with excellent structural properties are efficiently internalized by the endocytosis and successfully deliver Cur and CP molecules into the cytosol. Furthermore, the presence of Cur photosensitizer in the nanochannels of MSNs resulted in increased levels of cellular reactive oxygen species (ROS) under light irradiation. Thus, IBN-1-Cur-CP showed excellent anti-cancer therapy in the face of MES-SA/DX5 resistance cancer cells, owing to the synergistic effects of chemo- and photodynamic treatment.
最近，利用不同物理或化学途径的抗癌方法已从单一疗法转向协同疗法，这种疗法可以增强治疗效果。因此，人们付出了巨大努力来开发各种包裹双药的递送系统，以产生协同效应并对抗癌细胞获得性耐药。在本研究中，我们展示了如何制备基于生物工程与纳米技术研究所（IBN）-1的介孔二氧化硅纳米颗粒（MSN）用于多功能药物递送，以克服耐药性癌症治疗。最初，通过简单的一锅共缩合合成嵌入姜黄素（Cur）的IBN-1纳米复合材料（IBN-1-Cur），然后将顺铂（CP）的前药固定在羧酸盐修饰的表面上（IBN-1-Cur-CP），以在一个平台上分别实现光动力疗法（PDT）和化疗，用于对抗MES-SA/DX5癌细胞的多药耐药性（MDR）。作为结构导向剂的普朗尼克F127三嵌段共聚物在纳米颗粒中充当P-糖蛋白（p-gp）抑制剂。这些具有优异结构性能的设计杂化纳米复合材料通过内吞作用有效地内化，并成功地将Cur和CP分子递送到细胞质中。此外，MSN纳米通道中Cur光敏剂的存在导致在光照下细胞活性氧（ROS）水平升高。因此，由于化学疗法和光动力疗法的协同作用，IBN-1-Cur-CP在面对MES-SA/DX5耐药癌细胞时表现出优异的抗癌治疗效果。
